Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 9, 1265-1266 (1 October 2003) | doi:10.1038/nm928;
Genetic deficiency in Pparg does not alter development of experimental prostate cancer
&
Abstract
The role of the nuclear peroxisome proliferator–activated receptor (PPAR)-γ in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).